CJC-1295: GHRH Analogue — Complete Scientific Analysis

CJC-1295 is a synthetic GHRH (Growth Hormone-Releasing Hormone) analogue with an extended half-life via DAC (Drug Affinity Complex) chemical modification, which allows transient binding to serum albumin. According to clinical studies published in JCEM, it stimulates sustained GH and IGF-1 release (up to 7–14 days after a single dose) in anterior pituitary somatotroph cells.

CJC-1295 without DAC (Mod-GRF 1-29) has a half-life of ~30 minutes, producing acute physiological GH pulses. The DAC version binds to serum albumin, extending half-life to 5.8–8.1 days (Teichman et al., JCEM 2005 — PMID 16352683), with a more continuous profile of GH axis stimulation.

CJC-1295 binds to the GHRH-R receptor on anterior pituitary somatotroph cells. This binding activates adenylate cyclase via Gs protein, elevating intracellular cAMP, activating PKA and phosphorylating CREB, culminating in GH gene transcription and secretory vesicle exocytosis. The GH→hepatic IGF-1 axis mediates the anabolic and metabolic effects.

Yes. Two clinical trials published in the Journal of Clinical Endocrinology & Metabolism document effects in humans: Teichman et al. 2005 (PMID 16352683) — RCT with GH and IGF-1 elevation for up to 28 days; Ionescu & Frohman 2006 (PMID 17018654) — pulsatility study demonstrating preservation of physiological GH rhythm with CJC-1295.

According to data from Teichman et al. (PMID 16352683), multiple weekly doses of CJC-1295 maintained IGF-1 above baseline for up to 28 days, with elevations of 1.5–3x after a single dose. Hepatic IGF-1 mediates most of the body composition effects described in the literature.

According to Ionescu & Frohman (PMID 17018654), CJC-1295 administration increased basal GH levels (7.5x) and IGF-1 (45%) with preserved pulsatility: frequency and magnitude of GH pulses were not altered. This suggests GHRH-R can be continuously stimulated without abolishing physiological pulsatile secretion.

CJC-1295 has no FDA, EMA, or equivalent approval for general human clinical use. It is classified as a research peptide. Two approved GHRH analogues exist: Tesamorelin (FDA-approved for HIV lipodystrophy) and Sermorelin (restricted use in some countries for pediatric GH deficiency). CJC-1295 never progressed to phase III regulatory approval.

In available clinical studies (Teichman et al. 2005), reported adverse effects included: transient flushing, headache, and injection site reactions. No serious adverse events were reported in these populations. However, long-term human safety data are absent. Excess GH can cause fluid retention, arthralgia, insulin resistance, and other effects requiring monitoring.

CJC-1295 (GHRH agonist) and Ipamorelin (GHS-R1a/ghrelin agonist) act on distinct receptors with complementary mechanisms: GHRH increases GH pulse amplitude, while secretagogues like Ipamorelin increase frequency and inhibit somatostatin. The literature describes synergism in GH release. No direct combination clinical trial exists; extrapolation is pharmacological.

Both are GHRH analogues, but with important differences: Tesamorelin has FDA indication for abdominal lipodystrophy in HIV, with multiple phase III trials. CJC-1295 has only two phase I/II human studies and never obtained regulatory approval. Tesamorelin has more robust body composition efficacy data; CJC-1295 offers dosing convenience (1x/week vs. 1x/day).

Indirectly, via GH and IGF-1 elevation, the literature describes anabolic effects on body composition: increased muscle protein synthesis, visceral lipolysis, and nitrogen retention. Review by Hersch & Merriam (PMID 18488883) discusses that GH secretagogues improve body composition in GH-deficient adults, but effects in normal aging are inconsistent.

Long-term human safety data are absent. Available studies (maximum 28–49 days) detected no serious adverse events. Chronic GH-IGF-1 axis stimulation raises theoretical concerns about insulin resistance, proliferative risk, and other GH-dependent effects. Qualified endocrinological professional evaluation is indispensable before any consideration of use.